Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 9, 2009, Pages 1832-1840

  Domenech, Oscar ^a   Francius, Grégory ^b   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a   Dufrêne, Yves ^b   Mingeot Leclercq, Marie Paule ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

AFM; Calcein release; Cardiolipin; Membrane permeability; Oritavancin; POPC; POPE; POPG; Vancomycin

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; CALCEIN; CARDIOLIPIN; GLYCOPEPTIDE; LIPID; LIPOSOME; ORITAVANCIN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; VANCOMYCIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; GRAM POSITIVE BACTERIUM; MEMBRANE PERMEABILITY; MEMBRANE STRUCTURE; MOLECULAR INTERACTION; NANOANALYSIS; NONHUMAN; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ANALYSIS;

CARDIOLIPINS; GLYCOPEPTIDES; LIPID BILAYERS; MEMBRANE LIPIDS; MICROSCOPY, ATOMIC FORCE; PERMEABILITY; PHOSPHATIDYLETHANOLAMINES; UNILAMELLAR LIPOSOMES; VANCOMYCIN;

BACTERIA (MICROORGANISMS); EUKARYOTA; POSIBACTERIA;

EID: 68949173708     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.05.003     Document Type: Article

References (67)

1. Straus S.K., and Hancock R.E. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758 (2006) 1215-1223
2. Christ K., Wiedemann I., Bakowsky U., Sahl H.G., and Bendas G. The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques. Biochim. Biophys. Acta 1768 (2007) 694-704
3. Ghuysen J.M. Serine beta-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45 (1991) 37-67
4. Reynolds P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 943-950
5. Chambers H.F. Methicillin-resistant staphylococci. Clin. Microbiol. Rev. 1 (1988) 173-186
6. Rice L.B. Antimicrobial resistance in gram-positive bacteria. Am. J. Med. 119 (2006) S11-S19
7. Van Bambeke F., Mingeot-Leclercq M.P., Struelens M.J., and Tulkens P.M. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol. Sci. 29 (2008) 124-134
8. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7 (2006) 740-749
9. Allen N.E., and Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26 (2003) 511-532
10. Cooper R.D., Snyder N.J., Zweifel M.J., Staszak M.A., Wilkie S.C., Nicas T.I., et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot.(Tokyo) 49 (1996) 575-581
11. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4 (2004) 471-478
12. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 1127-1134
13. Belley A., Neesham-Grenon E., McKay G., Arhin F.F., Harris R., Beveridge T., et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus in vitro. Antimicrob. Agents Chemother 53 (2008) 918-925
14. Dufrene Y.F. Towards nanomicrobiology using atomic force microscopy. Nat.Rev.Microbiol. 6 (2008) 674-680
15. Trombe M.C., Laneelle M.A., and Laneelle G. Lipid composition of aminopterin-resistant and sensitive strains of Streptococcus pneumoniae. Effect of aminopterin inhibition. Biochim. Biophys. Acta 574 (1979) 290-300
16. Dowhan W. Molecular basis for membrane phospholipid diversity: why are there so many lipids?. Annu. Rev. Biochem. 66 (1997) 199-232
17. Beining P.R., Huff E., Prescott B., and Theodore T.S. Characterization of the lipids of mesosomal vesicles and plasma membranes from Staphylococcus aureus. J. Bacteriol. 121 (1975) 137-143
18. Cohen M., and Panos C. Membrane lipid composition of Streptococcus pyogenes and derived L form. Biochemistry 5 (1966) 2385-2392
19. Short S.A., and White D.C. Metabolism of the glycosyl diglycerides and phosphatidylglucose of Staphylococcus aureus. J. Bacteriol. 104 (1970) 126-132
20. Epand R.F., Savage P.B., and Epand R.M. Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (ceragenins). Biochim. Biophys. Acta 1768 (2007) 2500-2509
21. Van Bambeke F., Mingeot-Leclercq M.P., Schanck A., Brasseur R., and Tulkens P.M. Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. Eur. J. Pharmacol. 247 (1993) 155-168
22. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 234 (1959) 469-471
23. Weinstein J.N., Yoshikami S., Henkart P., Blumenthal R., and Hagins W.A. Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. Science 195 (1977) 489-492
24. Seral C., Van Bambeke F., and Tulkens P.M. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47 (2003) 2283-2292
25. Arhin F.F., Tomfohrde K., Draghi D.C., Aranza M., Parr T.R., Sahm D.F., et al. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters. Diagn. Microbiol. Infect. Dis. 62 (2008) 92-95
26. Domenech O., Merino-Montero S., Montero MT., and Hernandez-Borrell J. Surface planar bilayers of phospholipids used in protein membrane reconstitution: an atomic force microscopy study. Colloids Surf., B Biointerfaces 47 (2006) 102-106
27. Barcia-Macay M., Lemaire S., Mingeot-Leclercq M.P., Tulkens P.M., and Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58 (2006) 1177-1184
28. Barcia-Macay M., Seral C., Mingeot-Leclercq M.P., Tulkens P.M., and Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50 (2006) 841-851
29. Nannini E.C., and Stryjewski M.E. A new lipoglycopeptide: telavancin. Expert Opin. Pharmacother. 9 (2008) 2197-2207
30. Poulakou G., and Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert. Opin. Investig. Drugs 17 (2008) 225-243
31. Barna J.C., and Williams D.H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38 (1984) 339-357
32. Mingeot-Leclercq M.P., Gallet X., Flore C., Van Bambeke F., Peuvot J., and Brasseur R. Experimental and conformational analyses of interactions between butenafine and lipids. Antimicrob. Agents Chemother. 45 (2001) 3347-3354
33. Bechinger B. Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethici. J. Membr. Biol. 156 (1997) 197-211
34. Fimland G., Johnsen L., Dalhus B., and Nissen-Meyer J. Pediocin-like antimicrobial peptides (class IIa bacteriocins) and their immunity proteins: biosynthesis, structure, and mode of action. J. Pept. Sci. 11 (2005) 688-696
35. Porcelli F., Verardi R., Shi L., Henzler-Wildman K.A., Ramamoorthy A., and Veglia G. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry 47 (2008) 5565-5572
36. Campagna S., Saint N., Molle G., and Aumelas A. Structure and mechanism of action of the antimicrobial peptide piscidin. Biochemistry 46 (2007) 1771-1778
37. Heerklotz H., and Seelig J. Leakage and lysis of lipid membranes induced by the lipopeptide surfactin. Eur. Biophys. J. 36 (2007) 305-314
38. Park S.C., Kim M.H., Hossain M.A., Shin S.Y., Kim Y., Stella L., et al. Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions. Biochim. Biophys. Acta 1778 (2008) 229-241
39. Som A., and Tew G.N. Influence of lipid composition on membrane activity of antimicrobial phenylene ethynylene oligomers. J. Phys. Chem. B 112 (2008) 3495-3502
40. Zhao H., Sood R., Jutila A., Bose S., Fimland G., Nissen-Meyer J., et al. Interaction of the antimicrobial peptide pheromone Plantaricin A with model membranes: implications for a novel mechanism of action. Biochim. Biophys. Acta 1758 (2006) 1461-1474
41. Hallock K.J., Lee D.K., Omnaas J., Mosberg H.I., and Ramamoorthy A. Membrane composition determines pardaxin's mechanism of lipid bilayer disruption. Biophys. J. 83 (2002) 1004-1013
42. Murzyn K., Rog T., and Pasenkiewicz-Gierula M. Phosphatidylethanolamine-phosphatidylglycerol bilayer as a model of the inner bacterial membrane. Biophys. J. 88 (2005) 1091-1103
43. Rog T., Murzyn K., Gurbiel R., Takaoka Y., Kusumi A., and Pasenkiewicz-Gierula M. Effects of phospholipid unsaturation on the bilayer nonpolar region: a molecular simulation study. J. Lipid Res. 45 (2004) 326-336
44. Hope M.J., Walker D.C., and Cullis P.R. Ca2+ and pH induced fusion of small unilamellar vesicles consisting of phosphatidylethanolamine and negatively charged phospholipids: a freeze fracture study. Biochem. Biophys. Res. Commun. 110 (1983) 15-22
45. Farren S.B., and Cullis P.R. Polymorphism of phosphatidylglycerol-phosphatidylethanolamine model membrane systems: a 31p NMR study. Biochem. Biophys. Res. Commun. 97 (1980) 182-191
46. Epand R.M., and Bottega R. Determination of the phase behaviour of phosphatidylethanolamine admixed with other lipids and the effects of calcium chloride: implications for protein kinase C regulation. Biochim. Biophys. Acta 944 (1988) 144-154
47. Fyfe P.K., McAuley K.E., Roszak A.W., Isaacs N.W., Cogdell R.J., and Jones M.R. Probing the interface between membrane proteins and membrane lipids by X-ray crystallography. Trends Biochem. Sci. 26 (2001) 106-112
48. Rappolt M., Hickel A., Bringezu F., and Lohner K. Mechanism of the lamellar/inverse hexagonal phase transition examined by high resolution X-ray diffraction. Biophys. J. 84 (2003) 3111-3122
49. Ding J.L., Li P., and Ho B. The sushi peptides: structural characterization and mode of action against Gram-negative bacteria. Cell Mol. Life Sci. 65 (2008) 1202-1219
50. Rakotomanga M., Saint-Pierre-Chazalet M., and Loiseau P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 49 (2005) 2677-2686
51. Domenech O., Sanz F., Montero M.T., and Hernandez-Borrell J. Thermodynamic and structural study of the main phospholipid components comprising the mitochondrial inner membrane. Biochim. Biophys. Acta 1758 (2006) 213-221
52. Domenech O., Morros A., Cabanas M.E., Montero M.T., and Hernandez-Borrell J. Thermal response of domains in cardiolipin content bilayers. Ultramicroscopy 107 (2007) 943-947
53. Kell D.B. On the functional proton current pathway of electron transport phosphorylation, an electrodic view. Biochim. Biophys. Acta 549 (1979) 55-99
54. Lin G., Credito K., Ednie L.M., and Appelbaum P.C. Antistaphylococcal activity of dalbavancin, an experimental glycopeptides. Antimicrob. Agents Chemother. 49 (2005) 770-772
55. Bhavnani S.M., Passarell J.A., Owen J.S., Loutit J.S., Porter S.B., and Ambrose P.G. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50 (2006) 994-1000
56. Krogstad D.J., and Pargwette A.R. Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob. Agents Chemother. 17 (1980) 965-968
57. Novak R., Henriques B., Charpentier E., Normark S., and Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399 (1999) 590-593
58. Novak R., Charpentier E., Braun J.S., and Tuomanen E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol. Cell 5 (2000) 49-57
59. Kim S.J., Cegelski L., Stueber D., Singh M., Dietrich E., Tanaka K.S., et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J. Mol. Biol. 377 (2008) 281-293
60. Kim S.J., Cegelski L., Preobrazhenskaya M., and Schaefer J. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C(92) and 15N(93) rotational-echo double resonance. Biochemistry 45 (2006) 5235-5250
61. Cooper M.A., and Williams D.H. Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium. Chem. Biol. 6 (1999) 891-899
62. Beauregard D.A., Maguire A.J., Williams D.H., and Reynolds P.E. Semiquantitation of cooperativity in binding of vancomycin-group antibiotics to vancomycin-susceptible and-resistant organisms. Antimicrob. Agents Chemother. 41 (1997) 2418-2423
63. Scocchi M., Zelezetsky I., Benincasa M., Gennaro R., Mazzoli A., and Tossi A. Structural aspects and biological properties of the cathelicidin PMAP-36. FEBS J. 272 (2005) 4398-4406
64. Dempsey C.E., Ueno S., and Avison M.B. Enhanced membrane permeabilization and antibacterial activity of a disulfide-dimerized magainin analogue. Biochemistry 42 (2003) 402-409
65. Lehmann C., Bunkoczi G., Vertesy L., and Sheldrick G.M. Structures of glycopeptide antibiotics with peptides that model bacterial cell-wall precursors. J. Mol. Biol. 318 (2002) 723-732
66. Cooper DM., and Crossthwaite A.J. Higher-order organization and regulation of adenylyl cyclases. Trends Pharmacol. Sci. 27 (2006) 426-431
67. Jia Y., Gonzalez-Zamora E., Ma N., Liu Z., Bois-Choussy M., Malabarba A., et al. Identification of synthetic compounds active against VRE: the role of the lipidated aminoglucose and the structure of glycopeptide binding pocket. Bioorg. Med. Chem. Lett. 15 (2005) 4594-4599